/TLSA
TLSA Stock - Tiziana Life Sciences Ltd
Healthcare|BiotechnologyNASDAQ
$1.52+5.56%
+$0.08 (+5.56%) • Dec 19
61
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.26
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.67
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TLSA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.50 – $1.54
TARGET (TP)$1.75
STOP LOSS$1.40
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.23
52W High$2.60
52W Low$0.63
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-15,794,000 | $-17,984,000 | $-14,586,000 | $-27,374,000 | $-28,026,000 |
| Net Income | $-11,863,000 | $-17,691,000 | $-15,397,000 | $-23,417,000 | $-26,131,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.22 | $-0.34 | $-0.30 | $-0.48 | $-0.54 |
Company Overview
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
TLSABeat Rate
20%
Last 5 quarters
Avg Surprise
-158.8%
EPS vs Estimate
Beats / Misses
1/4
Last 12 quarters
Latest EPS
$-0.06
Q2 2025
EPS Surprise History
Q3 20
-536.8%
$-0.06vs$-0.01
Q2 21
-46.9%
$-0.08vs$-0.05
Q3 21
-253.2%
$-0.20vs$-0.06
Q3 22
No data
Q4 22
No data
Q3 23
No data
Q1 24
No data
Q2 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 8, 2026 | — | — | — | — |
Q4 2025 | Oct 13, 2025 | — | — | — | — |
Q2 2025 | Jun 23, 2025 | — | — | — | — |
Q2 2025 | May 20, 2025 | — | $-0.06 | — | — |
Q4 2024 | Oct 18, 2024 | — | — | — | — |
Q2 2024 | May 11, 2024 | — | — | — | — |
Q1 2024 | Jan 8, 2024 | — | $-0.22 | — | — |
Q4 2023 | Oct 3, 2023 | — | — | — | — |
Q3 2023 | Jul 26, 2023 | — | $-0.21 | — | — |
Q2 2023 | Apr 26, 2023 | — | — | — | — |
Q4 2022 | Dec 27, 2022 | — | $-0.27 | — | — |
Q3 2022 | Aug 19, 2022 | — | $-0.11 | — | — |
Q3 2021 | Sep 24, 2021 | $-0.06 | $-0.20 | -253.2% | ✗ MISS |
Q2 2021 | May 17, 2021 | $-0.05 | $-0.08 | -46.9% | ✗ MISS |
Q3 2020 | Sep 30, 2020 | $-0.01 | $-0.06 | -536.8% | ✗ MISS |
Q2 2020 | Jun 17, 2020 | $-0.02 | $-0.03 | -20.3% | ✗ MISS |
Q4 2019 | Dec 31, 2019 | — | $-0.07 | — | — |
Q3 2019 | Sep 30, 2019 | $-0.04 | $-0.01 | +63.4% | ✓ BEAT |
Q2 2019 | Jun 30, 2019 | — | $-0.07 | — | — |
Q2 2019 | Apr 4, 2019 | $-0.01 | — | — | — |
Latest News
Tiziana Life Sciences Executive Chairman Gabriele Cerrone Acquires 97,687 Company Common Shares
📈 PositiveBenzinga•Dec 19, 2025, 04:02 PM
Tiziana Life Sciences Doses First Participant With Intranasal Foralumab In Phase 2 Clinical Study Evaluating Patients With Early Alzheimer's Disease
📈 PositiveBenzinga•Dec 17, 2025, 01:52 PM
Tiziana Life Sciences CEO Ivor Elrifi Buys 163,400 Shares In Open Market, Increases Total Holdings To 357,848 Shares
📈 PositiveBenzinga•Dec 15, 2025, 08:09 PM
TLSA stock has given up its prior gain. Tiziana Life Sciences shares were trading higher after the company announced the withdrawal of its proposed public offering.
➖ NeutralBenzinga•Dec 15, 2025, 02:13 PM
Tiziana Life Sciences shares are trading higher after the company announced the withdrawal of its proposed public offering.
📈 PositiveBenzinga•Dec 15, 2025, 12:45 PM
Tiziana Life Sciences Announced The Withdrawal Of The Proposed Public Offering Of Common Shares Due To Market Conditions
📉 NegativeBenzinga•Dec 15, 2025, 12:35 PM
Tiziana Life Sciences Files For Common Stock Offering, Size Not Disclosed
➖ NeutralBenzinga•Dec 12, 2025, 10:39 PM
Tiziana Life Sciences Begins Enrollment In Phase 2 Alzheimer's Trial Of Intranasal Foralumab, Plans First Dosing Next Week As New PET Data Shows Persistent Neuroinflammation Despite Leqembi Treatment
📈 PositiveBenzinga•Dec 12, 2025, 07:12 PM
Tiziana Life Sciences Plans Spinout Of TZLS-501 Into Separate Publicly Traded Company To Enhance Strategic Focus And Drive Shareholder Value
📈 PositiveBenzinga•Dec 2, 2025, 12:06 PM
Tiziana Life Sciences' Phase 2 Clinical Trial Evaluating Intranasal Foralumab In ALS Patients Accepted For Inclusion In ALS MyMatch Program
📈 PositiveBenzinga•Nov 25, 2025, 01:33 PM
Tiziana Life Sciences To Present At BIO-Europe 2025, Highlighting Nasal Delivery Platform And Lead Candidate, Intranasal Foralumab, Fully Human Anti-CD3 Monoclonal Antibody In Clinical Development
📈 PositiveBenzinga•Oct 29, 2025, 11:25 AM
Tiziana Announces It Will Advance Its Second Asset, A Fully Human anti-IL-6 receptor Monoclonal Antibody, TZLS-501; Tiziana Will Pursue Non-Dilutive Funding Strategies For The Development Of TZLS-501 While Continuing To Advance Intranasal Foralumab As Its Lead Program.
📈 PositiveBenzinga•Sep 25, 2025, 12:34 PM
Tiziana Life Sciences Granted Department Of Defense Grant To Support Three-Year Study Of Its Intranasal Anti-CD3 Therapy For Spinal Cord Injury
📈 PositiveBenzinga•Sep 15, 2025, 12:08 PM
Tiziana Life Sciences Announces CEO Ivor Elrifi Purchased 193,848 Shares At $1.65/Share
📈 PositiveBenzinga•Sep 9, 2025, 12:36 PM
TLSA stock has given up its prior gain. Tiziana Life Sciences shares were trading higher after the company announced its Chairman, Gabriele Cerrone, bought 25,000 shares at $1.60 per share.
➖ NeutralBenzinga•Sep 5, 2025, 02:29 PM
Tiziana Life Sciences shares are trading higher after the company announced its Chairman, Gabriele Cerrone, bought 25,000 shares at $1.60 per share.
📈 PositiveBenzinga•Sep 5, 2025, 01:25 PM
Tiziana Life Sciences Chairman Gabriele Cerrone Buys 25K Shares At $1.60; Now Holds 36.28% Of Issued Capital
📈 PositiveBenzinga•Sep 5, 2025, 12:35 PM
Tiziana to begin testing foralumab in multiple system atrophy
📈 PositiveSeeking Alpha•Aug 11, 2025, 01:29 PM
Tiziana rises on positive results in multiple sclerosis treatment study
📈 PositiveSeeking Alpha•May 6, 2025, 01:08 PM
Frequently Asked Questions about TLSA
What is TLSA's current stock price?
Tiziana Life Sciences Ltd (TLSA) is currently trading at $1.52 per share. The stock has moved +5.56% today.
What is the analyst price target for TLSA?
No analyst price targets are currently available for this stock.
What sector is Tiziana Life Sciences Ltd in?
Tiziana Life Sciences Ltd operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is TLSA's market cap?
Tiziana Life Sciences Ltd has a market capitalization of $0.09 billion, making it a small-cap company.
Does TLSA pay dividends?
No, Tiziana Life Sciences Ltd does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANEB
Anebulo Pharmaceuticals, Inc.
$2.17
Mkt Cap: $0.1B
COYA
Coya Therapeutics, Inc.
$5.49
Mkt Cap: $0.1B
ESLA
Estrella Immunopharma, Inc.
$1.69
Mkt Cap: $0.1B
EXOZ
eXoZymes, Inc.
$12.30
Mkt Cap: $0.1B
IMMX
Immix Biopharma, Inc.
$5.72
Mkt Cap: $0.2B
MGNX
MacroGenics, Inc.
$1.50
Mkt Cap: $0.1B
OKYO
OKYO Pharma Limited
$2.03
Mkt Cap: $0.1B
PLRX
Pliant Therapeutics, Inc.
$1.23
Mkt Cap: $0.1B
WHWK
Whitehawk Therapeutics Inc
$2.56
Mkt Cap: $0.1B
ZNTL
Zentalis Pharmaceuticals, Inc.
$1.40
Mkt Cap: $0.1B
Explore stocks similar to TLSA for comparison